Integrating Care: MOUD and Infectious Disease

Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.

Join the Providers Clinical Support System (PCSS) MOUD and the National Council for Mental Wellbeing on Wednesday, Jan. 29, 1-2 p.m. ET, as we discuss these public health crises and the role that integrated opioid use disorder (OUD) and infectious disease care can play in reducing risk and improving health outcomes. Attendees will learn from expert medical professionals about the latest evidence-based practices for OUD and infectious disease care.

Educational objectives:

• Examine the connection between OUD and infectious disease.
• Discuss increased risk for infections among people with OUD.
• Describe the benefits of MOUD and integrated health care services in preventing and treating OUD and infectious disease.
• Identify barriers and solutions for access to MOUD services and infectious disease care.

Featured speakers:

• Daniel Rosa, MD, Sr. Medical Director, Acacia Network
• Christina Arredondo, MD, MPH, Medical Director of Behavioral Health and MAT, El Rio Community Health

Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from the Substance Abuse and Mental Health Services Administration. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. government.